Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Impedimed Limited ( (AU:IPD) ) has shared an announcement.
ImpediMed Limited announced a correction to its 2025 Remuneration Report, clarifying that the Board Chair’s fee will be paid 85% in cash and 15% in equity, aligning with the payment structure for other Non-executive Directors. This adjustment reflects the company’s commitment to transparency and consistency in its remuneration practices, which may impact stakeholder perceptions and corporate governance standards.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices for the assessment and monitoring of fluid status and body composition. The company primarily serves healthcare providers and patients, aiming to enhance clinical decision-making and patient outcomes.
Average Trading Volume: 1,667,962
Technical Sentiment Signal: Sell
Current Market Cap: A$81.45M
For an in-depth examination of IPD stock, go to TipRanks’ Overview page.